IP Portfolio

Protecting what we design

Axia Discovery has filed 11 U.S. provisional patent applications in 2026, establishing a patent-pending pipeline of de novo-designed cyclic peptide therapeutics across four therapeutic areas and 10 programs — led by oncology radioligand therapy — with PCT international filings anticipated.

U.S. provisional applications filed

Therapeutic areas

Disclosed programs

Eleven applications filed in 2026

U.S. provisional patent applications covering novel de novo-designed cyclic peptide compositions across oncology (radioligand therapy), CNS, cardiometabolic, and renal indications. Further filings staged as programs advance.

PCT international filings anticipated

Provisional applications establish priority dates. PCT international filings are planned to extend protection across key jurisdictions in line with partnering strategy.

Composition of matter

Filings protect the novel cyclic peptide compositions we design — covering the molecules themselves across their targeted indications.

Disclosed responsibly

Specific sequences, structural details, and claim language remain confidential until applications publish — standard practice for early-stage, file-first IP. Detailed status is shared under CDA.

Patent-pending programs

Program	Modality	Target	Indication	Status
AX-RLT-001	Cyclic peptide · RLT	Undisclosed	Castration-resistant prostate cancer (beyond current radioligand therapy)	Patent pending
AX-RLT-002	Cyclic peptide · RLT	Undisclosed	Prostate / ER+ breast cancer	Patent pending
AX-PDC-001	Cyclic peptide · composition IP	Undisclosed	Multiple myeloma	Patent pending
AX-PDC-002	Cyclic peptide · composition IP	Undisclosed	Solid tumors	Patent pending
AX-RLT-003	Cyclic peptide · RLT	Undisclosed	Endometrial carcinoma	Patent pending
AX-CP-001	Cyclic peptide antagonist	Undisclosed	Neurological disorders	Patent pending
AX-CP-002	Cyclic peptide · ant. + ago.	Undisclosed	Depression / anxiety · DEE / obesity	Patent pending
AX-CP-003	Cyclic peptide agonist	Undisclosed	Heart failure / PAH	Patent pending
AX-CP-004	Cyclic peptide	Undisclosed	Obesity / metabolic	Patent pending
AX-CP-005	Cyclic peptide · calcimimetic (PAM)	Undisclosed	Secondary hyperparathyroidism (CKD-MBD)	Patent pending

11 U.S. provisional patent applications filed 2026 (10 programs; AX-CP-002 covers two) · Application numbers confidential · PCT international filings anticipated

Full IP status — targets, sequences, and claim scope — shared under CDA.

Published and granted patents will be listed here as they issue.

Request CDA / Diligence Package